|
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
Jun 2023 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
Jul 2020 |
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
Jan 2019 |
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
|
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry |
Jan 2019 |
Am J Hematol |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
How I Diagnose Low-Grade Myelodysplastic Syndromes |
May 2020 |
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
Aug 2020 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision-making and treatment of myelodysplastic syndromes |
Dec 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
Mar 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal nocturnal hemoglobinuria: Where we stand |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
